Foundayo sales hit $184 million in Q3, bringing total revenue to $281 million since launch.
Last month, the EMA recommended the approval of Foundayo for adults with obesity.
Novo submitted the oral version of Wegovy for regulatory approval in August, but is yet to receive clearance.
Eli Lilly (LLY) has hit a major milestone in the world's second-biggest pharmaceutical market after Orforglipron, which is marketed as Foundayo, received approval in China.
https://finance.yahoo.com/healthcare/articles/eli-lilly-orforglipron-wins-big-105122158.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.